Pharmalink AB Elects Anders Wiklund as Chairman and Appoints Elisabeth Lindner to its Board of Directors

Anders Wiklund has gained a wealth of business and corporate development experience in the biotechnology and pharmaceutical industry from a career in Europe and the US spanning 40 years. He spent 29 years with the Kabi and Pharmacia group of companies, where he held a number of different positions, such as Managing Director of KabiVitrum in the UK, President of KabiVitrum International in Sweden, President and CEO of KabiVitrum and KabiPharmacia in the USA. Mr. Wiklund also currently serves on the boards of QuatRx Inc, EffRx SA, Clavis Pharma AS and Life Medical AB.

Ms. Elisabeth Lindner is one of Sweden's most experienced experts within the biopharmaceutical industry, with more than 25 years experience in senior management roles at Octapharma AB, Pharmacia Corporation and most recently as President and Chief Executive Officer at Diamyd Medical AB. Ms. Lindner is a Director at BioInvent International AB and Karo Bio AB, and serves as Director of the Royal Swedish Academy of Engineering Science. She holds an MSc from Stockholm University and an M.B.A from Uppsala University.

"With Anders taking on the Chairman's role and Elisabeth joining the Board, Pharmalink is positioned for the next stage of development," says Johan Häggblad, Managing Director of Pharmalink. "Nefecon and Busulipo are two highly promising product candidates under evaluation. Anders's and Elisabeth's exceptional industry experience will be invaluable in ensuring we realize value for Pharmalink and for patients with significant unmet medical need."

About Pharmalink

Pharmalink is a Swedish specialty pharma company developing high value products for niche indications. Pharmalink draws on its extensive experience of pharmaceutical product development and the excellence of medical science in Sweden to identify and progress products that address significant unmet medical needs. Pharmalink has introduced more than 15 pharmaceutical products to the market. Using a repurposing and reformulation strategy, Pharmalink minimizes the risk of product development. The Company's strategy is to apply its expertise to drive drug development and commercialize with partners. Pharmalink currently has two clinical phase projects under development, Nefecon® and BusulipoTM, and is actively in-licensing promising new projects to add to its pipeline. Visit http://www.pharmalink.se for further information.

For further information, please contact:

PharmalinkAB:
Johan Häggblad, Managing Director, +46(0)70-668-0644
Email: [email protected]
http://www.pharmalink.se

Citigate Dewe Rogerson:
Chris Gardner/ Nina Enegren, +44-207-638-9571